NFATc4-HDAC Mediated Repression of Atrophy Genes in Aging Skeletal Muscle

Hypothesis

NFATc4's constitutive nuclear presence in aged skeletal muscle directly represses the transcription of atrophy‑related E3 ligases MuRF1 and atrogin-1 by recruiting histone deacetylase complexes, thereby blunting a compensatory proteostatic response.

Mechanistic rationale

It's well known that NFATc4 binds to conserved NFAT sites in the promoters of MuRF1 and atrogin-1, a prediction supported by its known DNA‑binding domain and constitutive nuclear localization (3).

We're suggesting that chronic Ca²⁺ leak through ryanodine receptors in aging muscle elevates basal calcineurin activity, which may promote NFATc4 dephosphorylation and increase its affinity for co‑repressors such as HDAC1/2 or Sin3A (7).

Don't overlook that HDAC‑mediated deacetylation of histone H3K9/H3K27 at these promoters creates a closed chromatin state, reducing transcription despite upstream stress signals that would normally activate FoxO‑dependent expression (4).

This repression contrasts with the classic NFATc1‑driven slow‑fiber program, which relies on activity‑dependent nuclear translocation and co‑activator recruitment (1,2).

Testable predictions

1. ChIP‑qPCR in muscle extracts from young vs. old mice will show increased NFATc4 occupancy at the MuRF1 and atrogin-1 promoters in aged tissue, accompanied by enriched HDAC1/2 and reduced H3K9ac signal.

2. Genetic knockdown of NFATc4 (e.g., muscle‑specific shRNA or CRISPRi) in aged mice will lead to a significant rise in MuRF1/atrogin-1 mRNA and protein, reduced fiber cross‑sectional area, and improved muscle strength when assessed by grip test.

3. Pharmacological disruption of the NFATc4‑HDAC interaction (using a cell‑permeable peptide that blocks the NFATc4 repression domain) will attenuate the repression phenotype without affecting calcineurin‑NFATc1 signaling, which can be monitored by unchanged slow‑myosin heavy chain expression.

4. Rescue experiment: Overexpressing a NFATc4 mutant lacking the repression domain in young muscle will mimic the aged phenotype, causing low atrophy‑gene expression and increased susceptibility to proteotoxic stress.

Falsifiability

If any of the above assays fail to detect increased NFATc4 promoter binding, HDAC recruitment, or consequent changes in atrophy‑gene expression upon NFATc4 loss‑of‑function, the hypothesis that NFATc4 actively suppresses atrophy genes in aging muscle would be refuted. Conversely, confirmation would uncover a novel isoform‑specific brake on proteostatic remodeling, offering a fresh target for sarcopenia therapeutics.

Broader implications

This model reinterprets the paradox of downregulated MuRF1/atrogin-1 in sarcopenia not as a passive loss of signaling but as an active transcriptional brake. It suggests that therapeutic strategies aimed at modulating NFATc4‑corepressor interactions—rather than global calcineurin inhibition—could re‑enable adaptive atrophy pathways, allowing aged muscle to clear damaged proteins and regain homeostasis.